MJMohammad Jafferany

Mohammad Jafferany

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mohammad Jafferany has a total of 432 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Crawling Beneath the Surface: Exploring the Medical Conditions Associated With Delusional Infestation

    by Allison Meihofer, Nathan Sagasser, Rafael Aviles Encarnacion, Lauryn J. San Juan, Kennedy O'NEill, Salma Bennis, Colin Burnette, Jessica Colon, Melissa Perez, Mohammad Jafferany

    Background: Delusional infestation is characterized by a fixed false belief of infestation despite no objective evidence. Although traditionally considered a primary psychiatric disorder, it may occur secondary to underlying medical conditions. This review examined medical disorders associated with delusional infestation and their implications for diagnosis and management. Methods: The literature was reviewed for endocrine, neuropsychological, substance‐related, renal, hematologic, metabolic, and infectious conditions associated with delusional infestation, with emphasis on proposed mechanisms, diagnostic evaluation, and treatment response. Results: Delusional infestationwas associated with thyroid dysfunction, diabetes and peripheral neuropathy, dementia, Parkinson's disease and dopaminergic medications, cerebrovascular disease, major depressive disorder, stimulant use, end stage renal disease, iron deficiency, and HIV associated neurocognitive disorders. Proposed mechanisms included dopaminergic dysregulation, neuroinflammation, cognitive impairment, and misinterpretation of abnormal sensory stimuli. Improvement or resolution was frequently reported after treatment of the underlying condition, discontinuation of causative medications or substances, and use of antipsychotic therapy. Conclusion: Delusional infestation may represent a manifestation of an underlying and potentially reversible medical condition, supporting comprehensive evaluation and individualized, multidisciplinary management.

  • Open Access

    Association of Comorbid Trauma and Stressor‐Related Disorders in Pemphigus and Pemphigoid: A Case‐Control Study

    by Isabella J. Tan, Gaurav N. Pathak, Suraj S. Pathak, Babar K. Rao, Mohammad Jafferany


  • Open Access

    Psychodermatology of the Female: Hormones, Skin and Mental Health Across the Lifespan

    by Sheila Sharifi, Jessica Gulati, Veranca Shah, Keira Barr, Mohammad Jafferany

    Psychodermatology examines the bidirectional relationship between mental health and skin disease, offering an integrated approach to understanding the psychosocial impacts of dermatologic conditions. Intricate interactions between physiological stressors, immune system responses and hormonal signals are central to this relationship. For women, hormonal transitions throughout the lifespan play a critical role in modulating both skin pathophysiology and mental health. In this narrative review, we discuss how hormonal milestones, such as menstruation and pregnancy, contribute to cutaneous manifestations. We examine these fluctuations through the lens of the brain–skin axis and the Neuro‐Immuno‐Cutaneous‐Endocrine (NICE) network, which incorporates hormonal, immune and neural signals within the skin. Additionally, we draw attention to common psychiatric comorbidities that present alongside skin disorders, including depression, anxiety and body dysmorphia. By focusing on these challenges, we hope to highlight the unique psychosocial burdens faced by women with visible skin conditions and advocate for integrative treatment approaches. Ultimately, this review underscores the need for gender‐specific care that addresses the full spectrum of women's psychodermatologic health.


  • Standardizing screening for factitious skin disorders in dermatology

    by Isabella J Tan, Mohammad Jafferany

    Factitious skin disorders remain under-recognized in dermatology, which leads to repeated procedures, ineffective treatments and patient distress. We developed the Factitious Skin Disorder Inventory (FSDI), which is a brief, patient-administered screening tool that quantifies behavioural patterns, psychosocial impact and psychological distress to support early recognition and targeted intervention. The FSDI offers a practical, structured framework for clinical assessment and generates standardized data to guide future research and evidence-based management of this complex, under-recognized condition.


  • Open Access

    Psychopharmacology in Dermatology

    by Olivia Katamanin, Sheila Sharifi, Mohammad Jafferany

    Psychodermatology encompasses the complex relationship between psychiatric disorders and dermatologic conditions, focusing on their bidirectional effects. This review delves into the role of psychopharmacology in managing dermatologic diseases and their associated psychiatric comorbidities, specifically investigating how psychotropic medications, such as antidepressants, anxiolytics, and antipsychotics, are used to treat dermatologic conditions with psychiatric comorbidities and their impact on both skin health and psychiatric symptoms. A narrative review was conducted, synthesizing studies published between 2019 and 2024 that included studies focused on psychopharmacological interventions in psychocutaneous disorders. Relevant literature was analyzed to evaluate the efficacy of psychotropic medications in improving both dermatologic and psychiatric symptoms. The present review highlighted that psychotropic medications, particularly antidepressants, anxiolytics, and antipsychotics, offer significant benefits in managing psychodermatologic conditions. Across the literature, antidepressants were shown to reduce inflammation and immune dysregulation in conditions such as psoriasis and hidradenitis suppurativa. Furthermore, psychotropic drugs were shown to alleviate psychiatric symptoms associated with dermatologic diseases, such as anxiety, compulsive behaviors, and delusional thoughts. Although the literature has demonstrated the efficacy of psychotropic medication in treating dermatologic diseases, psychiatric referrals and psychopharmacological treatments remain underutilized in clinical practice. Psychopharmacology plays a crucial role in managing psychodermatologic conditions by addressing both skin and psychiatric symptoms. Despite growing evidence of the importance and utility of psychodermatology, there is a need for greater awareness and incorporation of multidisciplinary psychiatric evaluation and treatment in dermatologic care. Future research should focus on larger, longitudinal studies to assess the long-term efficacy and safety of psychotropic medications in dermatology.


  • Open Access

    Integrated CO 2 Laser Treatment and Cognitive–Behavioral Therapy for Postadolescent Acne Excoriée: Clinical Outcomes From a Case Series

    by Julian Penev, Milla Balabanova, Mohammad Jafferany

    Background: Self‐inflicted skin injury is a significant yet often underrecognized contributor to acne progression, particularly in postadolescent populations. It not only perpetuates lesions but also triggers inflammatory cascades, including sebaceous gland epithelialization and cystic transformation. Postadolescent acne excoriée poses unique therapeutic challenges due to the interplay of dermatological and psychological factors. Aims: To evaluate the effectiveness of a combined psychodermatological treatment—CO 2 laser ablation and cognitive–behavioral therapy (CBT)—in managing chronic, treatment‐resistant postadolescent acne excoriée. Methods: A case series of three patients with refractory postadolescent acne excoriée was conducted. Treatment involved CO 2 laser ablation to remove obstructed sebaceous glands, combined with CBT targeting maladaptive excoriation behaviors. Results: All patients achieved rapid and sustained clinical improvement. The combined approach disrupted the pathomimetic cycle, eliminated visible obstructed sebaceous glands, and reduced compulsive skin manipulation. Conclusion: Integrating CO 2 laser ablation with CBT offers a dual benefit of addressing both the physical lesions and psychological drivers of acne excoriée. Multidisciplinary collaboration is essential for effective management of complex psychocutaneous disorders.

  • Open Access

    Novel and existing therapeutic interventions in psychogenic pruritus

    by Hira Ghani, Sasha Ghofrani, Nina Modanlo, Nithisha Cheedalla, Mohammad Jafferany

    Psychogenic pruritus (PP) is a chronic itch disorder associated with psychological conditions lacking any dermatological or systemic cause. Diagnosis relies on excluding other aetiologies and identifying psychological stressors. Treatments include dermatological and psychiatric interventions such as topical steroids, selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, antihistamines, antipsychotics and psychotherapy. However, efficacy remains inconsistent, necessitating a systematic review of current and emerging pharmacological options. This study reviews pharmacological treatments for PP published in the past decade, evaluating efficacy and therapeutic potential. A systematic literature search was conducted using PubMed, Embase and Google Scholar (November 2014 to November 2024) following the PRISMA guidelines (PROSPERO: 1000201). In total, 1034 articles were screened by two independent reviewers. Inclusion criteria focused on human studies evaluating pharmacological treatments for PP. Seven studies met the inclusion criteria. Levels of evidence were assessed using the Joanna Briggs Institute critical appraisal checklist. SSRIs, particularly escitalopram, showed symptom improvement in case reports. Naltrexone (an opioid antagonist) led to complete itch resolution in a patient refractory to SSRIs. Gabapentin reduced pruritus severity. A neurokinin-1 receptor (NK-1R) antagonist (serlopitant) demonstrated significant efficacy in a phase II trial. Biologics such as dupilumab showed promise in chronic pruritus. Targeted therapies, including SSRIs, naltrexone, opioid pathway modulators, NK-1R antagonists and biologics, show promise in the clinical management of PP, but further research through randomized controlled trials is necessary to establish their efficacy and optimize treatment strategies.


  • Open Access

    The Impact of Psoriasis Treatment on Depression and Suicide Risk: A Systematic Review

    by Behnoosh Shahsavaripoor, Shaghayegh Karami, Ali Sahebi, Mohammad Jafferany

    Background: Psoriasis is a long‐lasting inflammatory condition of the skin associated with various comorbidities, including depression and suicidal ideation. Management strategies for psoriasis include symptom alleviation, quality‐of‐life enhancement, and prevention of disease progression. Psoriasis treatments include topical therapies, phototherapy, oral systemic medications, and biologics. Objectives: In this review, we evaluate the impact of psoriasis treatments on depression and suicidal ideation in affected patients. Methods: We systematically searched multiple databases, including PubMed, Scopus, and Web of Science, until September 30, 2024, to identify relevant articles. Studies that examined the effects of psoriasis therapies on depression and suicidal thoughts were included. Data on treatment modalities, psychological health outcomes, and psoriasis severity was obtained. Quality evaluation instruments, such as JBI, consolidated standards of reporting trials (CONSORTs), Center for Evidence‐Based Management (CEMBa), and appraisal tool for cross‐sectional studies (AXIS), were used to appraise study quality. Results: Ten studies met inclusion criteria, predominantly focusing on biologic therapies. Biologics like guselkumab, brodalumab, and bimekizumab have shown notable reductions in depression symptoms, probably through the alleviation of psoriasis severity and the enhancement of quality‐of‐life. Suicidal ideation occurred in some cases, especially with brodalumab; however, a definitive causal relationship was not established. Conclusions: Treatments for psoriasis, especially biologics, have shown some advantages in reducing depression symptoms as well as relieving skin symptoms. However, cautious monitoring is required due to the possible hazards of suicidal thoughts with certain therapeutic options such as biologics. Addressing the complex issues of psoriasis requires comprehensive therapy that includes dermatologists and mental health specialists.

  • Open Access

    Neuropsychiatric Outcomes of IL ‐17 and IL ‐23 Inhibitors in Dermatology: Risks, Benefits, and Clinical Implications

    by Isabella J. Tan, Alexis Mitelman, Mohammad Jafferany